A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents
Open Access
- 26 September 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 30 (8) , 923-931
Abstract
Long-term polymer residue in the coronary milieu is a consequence of current drug-eluting stent (DES) therapy and has been implicated in late adverse events. We developed a novel polymer-free rapamycin- and probucol-eluting stent (Dual-DES) and compared its efficacy against commercially available permanent polymer-based sirolimus-eluting (SES; Cypher) and zotarolimus-eluting (ZES; Endeavor) stents. Between March 2006 and July 2007, a total of 1007 patients undergoing coronary stenting of de novo lesions, in native vessels, were randomized to treatment with SES (n = 335), Dual-DES (n = 333), or ZES (n = 339). The primary endpoint was binary angiographic restenosis at 6–8 month follow-up angiography. Secondary endpoints were angiographic in-stent late loss; and target lesion revascularization (TLR), death/myocardial infarction and stent thrombosis at 12 months. Follow-up angiographic data were available for 828 (82.2%) patients. There was a significant difference in both binary restenosis and TLR across treatment groups (P = 0.003 and P < 0.001, respectively). Binary restenosis in the Dual-DES group (11.0%) was significantly lower than that in the ZES group (19.3%; P = 0.002) but comparable with that in the SES group (12.0%; P = 0.68). Similarly, TLR with Dual-DES (6.8%) was significantly lower than ZES (13.6%; P = 0.001) but not different to that of SES (7.2%; P = 0.83). These differences were mirrored in the extent of late loss across the groups. No differences were observed between stent groups in terms of death/myocardial infarction or stent thrombosis. A novel polymer-free Dual-DES is associated with high anti-restenotic efficacy without recourse to carrier polymer. Potential long-term clinical advantage of this platform remains subject to investigation. Study registered at ClinicalTrials.gov. Identifier number: NCT00332397.Keywords
This publication has 36 references indexed in Scilit:
- The pre-clinical assessment of rapamycin-eluting, durable polymer-free stent coating conceptsBiomaterials, 2009
- Duration of antiplatelet therapy following intracoronary stenting: are changes needed?European Heart Journal Supplements, 2008
- Drug for a while, polymer for life: Is it a good solution?Catheterization and Cardiovascular Interventions, 2008
- Restenosis following implantation of bare metal coronary stents: Pathophysiology and pathways involved in the vascular response to injuryAdvanced Drug Delivery Reviews, 2006
- Randomized Trial of a Nonpolymer-Based Rapamycin-Eluting Stent Versus a Polymer-Based Paclitaxel-Eluting Stent for the Reduction of Late Lumen LossCirculation, 2006
- Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coatingEuropean Heart Journal, 2005
- Inhibition of Neointima Formation by a Novel Drug-Eluting Stent System That Allows for Dose-Adjustable, Multiple, and On-Site Stent CoatingArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Six- and Twelve-Month Results From First Human Experience Using Everolimus-Eluting Stents With Bioabsorbable PolymerCirculation, 2004
- Localized Hypersensitivity and Late Coronary Thrombosis Secondary to a Sirolimus-Eluting StentCirculation, 2004
- Effect of antioxidant probucol for preventing stent restenosisCatheterization and Cardiovascular Interventions, 2002